Clinical Data

stock image of a glucose meter with a blood strip

Biotech

Rezolute stock sinks 87% as hypoglycemia drug fails ph. 3 test

Rezolute’s stock has plunged 87% after the company’s rare disease drug flunked the final clinical test ahead of a planned approval application.

James Waldron Dec 11, 2025 9:45am

obesity overweight weight loss weigh

Lilly's obesity triple threat tops phase 3 efficacy forecasts

Dec 11, 2025 8:15am

Lung

GRI touts IPF safety edge, lung function gains amid cash crunch

Dec 11, 2025 5:12am

An arrow incrementally going up stairs before pointing straight up Blue background

Roche links SERD to 30% breast cancer risk reduction in phase 3

Dec 10, 2025 8:15am

Basketball players hands reaching for a ball near the hoop during a professional game

Exicure scores in phase 2 multiple myeloma program

Dec 9, 2025 10:15am

JNJ

Fierce Pharma

ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma

Dec 9, 2025 7:30am